Evidence map›Paper›PMID 40456910›Full record

ArticleJournal of neurology2025

Spatial navigation deficits in early Alzheimer's disease: the role of biomarkers and APOE genotype.

Martina Laczó, Zuzana Svacova, Ondrej Lerch, Lukas Martinkovic, Monika Krejci, Zuzana Nedelska, Hana Horakova, Vaclav Matoska, Martin Vyhnalek, Jakub Hort and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martina LaczóMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Zuzana SvacovaMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Ondrej LerchMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Lukas MartinkovicMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Monika KrejciMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Zuzana NedelskaMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Hana HorakovaMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Vaclav MatoskaDepartment of Clinical Biochemistry, Hematology and Immunology, Na Homolce Hospital, Prague, Czechia.
Martin VyhnalekMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Jakub HortMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia.
Michael HornbergerNorwich Medical School, University of East Anglia, Norwich, UK.
Jan LaczóMemory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, Praha 5 - Motol, 150 06, Prague, Czechia. jan.laczo@lfmotol.cuni.cz.

Funding

Czech Science Foundation (GACR) 22-33968SGrant Agency of Charles University 40125Grant Agency of Charles University PRIMUS 22/MED/011Institutional Support of Excellence 3 2. LF UK 6980382Ministry of Health of the Czech Republic NW25-04-00337Ministry of Health of the Czech Republic-conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107) - Funded by the European Union - Next Generation EU LX22NPO5107
6 · The paper itself

Abstract

backgroundSpatial navigation deficits are early symptoms of Alzheimer's disease (AD). The apolipoprotein E (APOE) ε4 allele is the most important genetic risk factor for AD. This study investigated effects of APOE genotype on spatial navigation in biomarker-defined individuals with amnestic mild cognitive impairment (aMCI) and associations of AD biomarkers and atrophy of AD-related brain regions with spatial navigation.

methods107 participants, cognitively normal older adults (CN, n = 48) and aMCI individuals stratified into AD aMCI (n = 28) and non-AD aMCI (n = 31) groups, underwent cognitive assessment, brain MRI, and spatial navigation assessment using the Virtual Supermarket Test with egocentric and allocentric tasks and a self-report questionnaire. Cerebrospinal fluid (CSF) biomarkers (amyloid-β

resultsAD aMCI participants had the highest prevalence of APOE ε4 carriers and worst allocentric navigation. CSF levels of AD biomarkers and atrophy in AD-related brain regions were associated with worse allocentric navigation. Between-group differences in spatial navigation and associations with AD biomarkers and regional brain atrophy were not influenced by APOE genotype. Self-reported navigation ability was similar across groups and unrelated to spatial navigation performance.

conclusionsThese findings suggest that allocentric navigation deficits in aMCI individuals are predominantly driven by AD pathology, independent of APOE genotype. This highlights the role of AD pathology as measured by biomarkers, rather than genetic status, as a major factor in navigational impairment in aMCI, and emphasizes the assessment of spatial navigation as a valuable tool for early detection of AD.

Indexed as

Alzheimer DiseaseApolipoprotein E4Apolipoproteins ECognitive DysfunctionSpatial NavigationAgedAged, 80 and overAmyloid beta-PeptidesAtrophyBiomarkersBrainFemaleGenotypeHumansMagnetic Resonance ImagingMaleAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoprotein E4Apolipoproteins EBiomarkersPeptide Fragmentstau ProteinsAllocentric navigationAmyloid-βEgocentric navigationEntorhinal cortexHippocampusTau protein

Identifiers

PMID40456910
PMCPMC12130088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.